BRM is a successful biopharmaceutical company formed in 1996 by Dennis Guberski and Dr. Arthur Like of the University of Massachusetts Medical School (UMass). Over the course of 20 years the founders developed proprietary diabetes research models under the sponsorship of the National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK). BRM licensed this intellectual property portfolio from UMass in 1998 and since that time has used these proprietary tools to become one of the leading sources of customized preclinical contract research specializing in type 1 and type 2 diabetes.
BRM is a successful biopharmaceutical company formed in 1996 by Dennis Guberski and Dr. Arthur Like of the University of Massachusetts Medical School (UMass). Over the course of 20 years the founders developed proprietary diabetes research models under the sponsorship of the National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK). BRM licensed this intellectual property portfolio from UMass in 1998 and since that time has used these proprietary tools to become one of the leading sources of customized preclinical contract research specializing in type 1 and type 2 diabetes.
BRM has developed proprietary rat strains which are translatable models for the characterization of type 1 and type 2 diabetes as well as immune-related diseases. Its technical competencies include design and conducting studies in autoimmunity (type 1 diabetes, lupus, Rheumatoid Arthritis and Multiple Sclerosis), metabolic disease (type 2 diabetes, metabolic syndrome, obesity, dyslipidemia, liver and kidney function), virology, neurodegenerative diseases, diabetic complications (retinopathy, neuropathy, nephropathy, and encephalopathy including Alzheimer’s disease) specialized animal model development and the production and care of multiple species.
BRM's Capabilities in Virology, Viral Immunology and Pathology: HSV-1, HSV-2, Influenza, RSV, LCMV, and CMV. For more information, please visit our website at www.BRMCRO.com.
Baseado no AgileState 2010, irei apresentar algumas informações interessantes de como está a agilidade no mundo. Afinal de contas, porque agilidade é bom? Qual o ganho? Porque ser ágil? Quais o beneficios? Irei abordar alguns números sobre a adoção da agilidade no Brasil e no mundo. Também apresentando alguns case de sucesso.
BRM has developed proprietary rat strains which are translatable models for the characterization of type 1 and type 2 diabetes as well as immune-related diseases. Its technical competencies include design and conducting studies in autoimmunity (type 1 diabetes, lupus, Rheumatoid Arthritis and Multiple Sclerosis), metabolic disease (type 2 diabetes, metabolic syndrome, obesity, dyslipidemia, liver and kidney function), virology, neurodegenerative diseases, diabetic complications (retinopathy, neuropathy, nephropathy, and encephalopathy including Alzheimer’s disease) specialized animal model development and the production and care of multiple species.
BRM's Capabilities in Virology, Viral Immunology and Pathology: HSV-1, HSV-2, Influenza, RSV, LCMV, and CMV. For more information, please visit our website at www.BRMCRO.com.
Baseado no AgileState 2010, irei apresentar algumas informações interessantes de como está a agilidade no mundo. Afinal de contas, porque agilidade é bom? Qual o ganho? Porque ser ágil? Quais o beneficios? Irei abordar alguns números sobre a adoção da agilidade no Brasil e no mundo. Também apresentando alguns case de sucesso.
أفضل 11 موقع لعمل اختبارات إلكترونية (Slide Decks).pdfqorrectdm
مع تطور التكنولوجيا، أصبحت أنظمة وأدوات الامتحانات الإلكترونية جزءاً أساسياً من التعليم الحديث. في هذا العرض، سنستعرض أفضل الأنظمة والأدوات التي تساعد المؤسسات التعليمية على تحسين عمليات الامتحان وتقديم تجربة تعليمية متميزة.